This below is great news for Volpara (VHT) to gain even more traction for sales outside of the USA.
The difference with this news (compared to 9SP recent announcements on Visa and Microsoft collaboration) is that VHT have already 4 years of distribution relationship with GE (see 2015 news below)
Wellington, NZ, 22nd March 2019: Volpara Health Technologies ("Volpara"; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, today announces that it has expanded its arrangement with GE Healthcare to cover customers outside of the USA. The new arrangement enables GE Healthcare to distribute Volpara Solutions’ industry-leading VolparaDensity software to customers worldwide.
WELLINGTON, New Zealand, January 20, 2015 – To help improve breast cancer screening for the 40 percent of American women with dense breasts, Volpara Solutions announced today it has signed an agreement enabling GE Healthcare to distribute Volpara Solutions’ industry-leading suite of products including VolparaDensity, VolparaAnalytics and VolparaDoseRT.
Under the agreement, GE Healthcare customers will have the option to purchase from GE Healthcare Volpara Solutions’ innovative suite of quantitative breast imaging tools that enable personalized measurements of volumetric density, patient-specific dose, breast compression and other factors designed to provide critical insight for breast imaging quality and workflow.
“Volpara’s volumetric density and breast imaging software are powerful tools which provide reliable, quantitative imaging data to help optimize breast cancer detection and patient care. The objective and consistent measurement of breast density is critical to our ability to offer personalized breast evaluation and provide the right imaging test for the right woman,” said Dr. Kathy Schilling, medical director of Christine E. Lynn Women’s and Wellness Institute of Boca Raton Regional Hospital in Boca Raton, Florida.
To date, more than 4-million women have had their breast density analyzed, using VolparaDensity, which is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to help determine which women with dense breasts may benefit from additional screening, such as with the GE Invenia Automated Breast Ultrasound (ABUS).
VolparaAnalytics is a powerful, centralized dashboard that produces configurable reports for management of quality assurance, resource utilization, and breast imaging workflow. VolparaDose provides a standardized measurement of patient-specific dose with consistent dose results across mammography systems from different manufacturers.
